Interleukin-15 and Interleukin-15 Receptor ÃÂ± mRNA-engineered Dendritic Cells as Promising Candidates for Dendritic Cell-based Vaccination in Cancer Immunotherapy
- *Corresponding Author:
- Johan MJ Van den Bergh
Laboratory of Experimental Hematology
Antwerp University Hospital (UZA)
Wilrijkstraat 10, B-2650 Edegem, Belgium
Tel: +32 3 821 4112
Fax: +32 3 821 4456
E-mail: [email protected]
Received Date: December 14, 2015; Accepted Date: January 21, 2016; Accepted Date: January 23, 2016
Citation: den Bergh JMJV, Lion E, Anguille S, Van Tendeloo FI, Smits ELJM (2016) Interleukin-15 and Interleukin-15 Receptor α mRNA-Engineered Dendritic Cells as Promising Candidates for Dendritic Cell-Based Vaccination in CancerImmunotherapy. J Cancer Sci Ther 8:015-019. doi: 10.4172/1948-5956.1000381
Copyright: © 2016 den Bergh JMJV, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Dendritic cell (DC)-based tumor vaccination holds great potential and is intensively being studied in cancer immunotherapy. Although DC vaccination can result in a survival advantage as shown in various cancer types, there is still room for improvement. Therefore, current DC vaccines urge rigorous optimization in order to increase their immune stimulating capacities for induction of antitumor immunity. In this context, strategies where the interleukin (IL) 15 transpresentation mechanism is incorporated, appear to be of great value due to the activating potential of IL-15 towards IL-15Rβγ expressing cells, such as cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. In the past 5 years, our research group designed different strategies to generate IL-15-expressing DC with superior T cell and NK cell-activating properties. In this review, we briefly describe the design of our latest DC vaccine, in which DC are genetically engineered to transpresent IL-15 via mRNA electroporation and discuss the capacity of this newly designed DC vaccine to activate NK cells and CTLs. Overall, IL-15 transpresenting DC show the potential to activate antitumor immunity and are promising candidates for DC based cancer immunotherapy.